Mutational signature of aristolochic acid: Clue to the recognition of a global disease

DNA Repair

Volumn 44, Issue , 2016, Pages 205-211

  Rosenquist, Thomas A ^a   Grollman, Arthur P ^a  

^a STONY BROOK UNIVERSITY   (United States)

Author keywords

Aristolochia; Aristolochic acid; DNA repair; Endemic nephropathy; Environmental mutagen; Mutational signature; Upper urinary tract carcinoma

Indexed keywords

ARISTOLOCHIC ACID; ARISTOLOLACTAM; ENVIRONMENTAL MUTAGEN; ALKYLATING AGENT; CARCINOGEN; DNA ADDUCT;

CHINESE MEDICINE; DNA ADDUCT; DNA DAMAGE; EARLY CANCER DIAGNOSIS; GENE MUTATION; GENE SEQUENCE; HUMAN; INDUCED MUTATION; MUTAGENESIS; NONHUMAN; PRIORITY JOURNAL; REVIEW; URINARY TRACT CANCER; AGONISTS; ARISTOLOCHIA; BIOSYNTHESIS; BLADDER; CARCINOMA; CHEMICALLY INDUCED; CHEMISTRY; DNA REPAIR; DRUG EFFECTS; GENETIC PREDISPOSITION; GENETICS; KIDNEY; LIVER; METABOLISM; MUTATION; PATHOLOGY; TOXICITY; UROLOGIC NEOPLASMS;

ALKYLATING AGENTS; ARISTOLOCHIA; ARISTOLOCHIC ACIDS; CARCINOGENS; CARCINOMA; DNA ADDUCTS; DNA DAMAGE; DNA REPAIR; GENETIC PREDISPOSITION TO DISEASE; HUMANS; KIDNEY; LIVER; MUTATION; URINARY BLADDER; UROLOGIC NEOPLASMS;

EID: 84969801333     PISSN: 15687864     EISSN: 15687856     Source Type: Journal    
DOI: 10.1016/j.dnarep.2016.05.027     Document Type: Review

References (64)

1. [1] Grollman, A.P., Scarborough, J., Jelakovic, B., Aristolochic acid nephropathy: an environmental and iatrogenic disease. Fishbein, J., (eds.) Advances in Molecular Toxicology, 2009, Elsevier, Amsterdam, 211–222.
2. [2] Vanherweghem, J.L., Depierreux, M., Tielemans, C., Abramowicz, D., Dratwa, M., Jadoul, M., et al. Rapidly progressive interstitial renal fibrosis in young women: association with slimming regimen including Chinese herbs. Lancet 341 (1993), 387–391.
3. [3] Schmeiser, H.H., Bieler, C.A., Wiessler, M., van Ypersele de Strihou, C., Cosyns, J.P., Detection of DNA adducts formed by aristolochic acid in renal tissue from patients with Chinese herbs nephropathy. Cancer Res. 56 (1996), 2025–2028.
4. [4] Nortier, J.L., Martinez, M.C., Schmeiser, H.H., Arlt, V.M., Bieler, C.A., Petein, M., et al. Urothelial carcinoma associated with the use of a Chinese herb (Aristolochia fangchi). N. Engl. J. Med. 342 (2000), 1686–1692.
5. [5] Cosyns, J.P., Jadoul, M., Squifflet, J.P., De Plaen, J.F., Ferluga, D., van Ypersele de Strihou, C., Chinese herbs nephropathy: a clue to Balkan endemic nephropathy?. Kidney Int. 45 (1994), 1680–1688.
6. [6] Bamias, G., Boletis, J., Balkan nephropathy: evolution of our knowledge. Am. J. Kidney Dis. 52 (2008), 606–616.
7. [7] Hranjec, T., Kovac, A., Kos, J., Mao, W., Chen, J.J., Grollman, A.P., et al. Endemic nephropathy: the case for chronic poisoning by aristolochia. Croat. Med. J. 46 (2005), 116–125.
8. [8] Grollman, A.P., Shibutani, S., Moriya, M., Miller, F., Wu, L., Moll, U., et al. Aristolochic acid and the etiology of endemic (Balkan) nephropathy. Proc. Natl. Acad. Sci. U. S. A. 104 (2007), 12129–12134.
9. [9] Jelakovic, B., Karanovic, S., Vukovic-Lela, I., Miller, F., Edwards, K.L., Nikolic, J., et al. Aristolactam-DNA adducts are a biomarker of environmental exposure to aristolochic acid. Kidney Int. 81 (2012), 559–567.
10. [10] Aristolochic Acids, National Toxicology Program/Rep Carcinog (2011) p. 1532–1549.
11. [11] De Broe, M.E., Chinese herbs nephropathy and Balkan endemic nephropathy: toward a single entity, aristolochic acid nephropathy. Kidney Int. 81 (2012), 513–515.
12. [12] Lai, M.N., Wang, S.M., Chen, P.C., Chen, Y.Y., Wang, J.D., Population-based case-control study of chinese herbal products containing aristolochic acid and urinary tract cancer risk. J. Natl. Cancer Inst. 102 (2010), 179–186.
13. [13] Chen, C.H., Dickman, K.G., Moriya, M., Zavadil, J., Sidorenko, V.S., Edwards, K.L., et al. Aristolochic acid-associated urothelial cancer in Taiwan. Proc. Natl. Acad. Sci. U. S. A. 109 (2012), 8241–8246.
14. [14] Grollman, A.P., Aristolochic acid nephropathy: harbinger of a global iatrogenic disease. Environ. Mol. Mutagen. 54 (2013), 1–7.
15. [15] Grollman, A., Marcus, D., Global hazards of herbal remedies: lessons from Aristolochia. EMBO Rep. 17 (2016), 619–625.
16. [16] Shibutani, S., Kim, S.Y., Suzuki, N., 32P-Postlabeling DNA Damage Assay: PAGE, TLC and HPLC. DNA Repair Protocols: Eukaryotic Systems. Henderson, D.S., (eds.), 2nd ed., 2005, Humana Press Inc., Totawa, N.J, 307–321.
17. [17] Yun, B.H., Sidorenko, V.S., Rosenquist, T.A., Dickman, K.G., Grollman, A.P., Turesky, R.J., New approaches for biomonitoring exposure to the human carcinogen aristolochic acid. Toxicol. Res. 4 (2015), 763–776.
18. [18] Alexandrov, L.B., Nik-Zainal, S., Wedge, D.C., Aparicio, S.A., Behjati, S., Biankin, A.V., et al. Signatures of mutational processes in human cancer. Nature 500 (2013), 415–421.
19. [19] Alexandrov, L.B., Nik-Zainal, S., Wedge, D.C., Campbell, P.J., Stratton, M.R., Deciphering signatures of mutational processes operative in human cancer. Cell Rep. 3 (2013), 246–259.
20. [20] Hoang, M.L., Chen, C.H., Sidorenko, V.S., He, J., Dickman, K.G., Yun, B.H., et al. Mutational signature of aristolochic acid exposure as revealed by whole-exome sequencing. Sci. Transl. Med., 5, 2013, 197ra02.
21. [21] Poon, S.L., Pang, S.T., McPherson, J.R., Yu, W., Huang, K.K., Guan, P., et al. Genome-wide mutational signatures of aristolochic acid and its application as a screening tool. Sci. Transl. Med., 5, 2013, 197ra01.
22. [22] Hollstein, M., Moriya, M., Grollman, A.P., Olivier, M., Analysis of TP53 mutation spectra reveals the fingerprint of the potent environmental carcinogen, aristolochic acid. Mutat. Res., 2013.
23. [23] Poon, S.L., Huang, M.N., Choo, Y., McPherson, J.R., Yu, W., Heng, H.L., et al. Mutation signatures implicate aristolochic acid in bladder cancer development. Genome Med., 7, 2015, 38.
24. [24] Scelo, G., Riazalhosseini, Y., Greger, L., Letourneau, L., Gonzalez-Porta, M., Wozniak, M.B., et al. Variation in genomic landscape of clear cell renal cell carcinoma across Europe. Nat. Commun., 5, 2014, 5135.
25. [25] Turesky, R.J., Yun, B.H., Brennan, P., Mates, D., Jinga, V., Harnden, P., et al. Aristolochic acid exposure in Romania and implications for renal cell carcinoma. Br. J. Cancer 114 (2016), 76–80.
26. [26] Jelakovic, B., Castells, X., Tomic, K., Ardin, M., Karanovic, S., Zavadil, J., Renal cell carcinomas of chronic kidney disease patients harbor the mutational signature of carcinogenic aristolochic acid. Int. J. Cancer 136 (2015), 2967–2972.
27. [27] Zou, S., Li, J., Zhou, H., Frech, C., Jiang, X., Chu, J.S., et al. Mutational landscape of intrahepatic cholangiocarcinoma. Nat. Commun., 5, 2014, 5696.
28. [28] Borad, M.J., Champion, M.D., Egan, J.B., Liang, W.S., Fonseca, R., Bryce, A.H., et al. Integrated genomic characterization reveals novel, therapeutically relevant drug targets in FGFR and EGFR pathways in sporadic intrahepatic cholangiocarcinoma. PLoS Genet., 10, 2014, e1004135.
29. [29] Fujimoto, A., Furuta, M., Shiraishi, Y., Gotoh, K., Kawakami, Y., Arihiro, K., et al. Whole-genome mutational landscape of liver cancers displaying biliary phenotype reveals hepatitis impact and molecular diversity. Nat. Commun., 6, 2015, 6120.
30. [30] Jiao, Y., Pawlik, T.M., Anders, R.A., Selaru, F.M., Streppel, M.M., Lucas, D.J., et al. Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas. Nat. Genet. 45 (2013), 1470–1473.
31. [31] Sia, D., Losic, B., Moeini, A., Cabellos, L., Hao, K., Revill, K., et al. Massive parallel sequencing uncovers actionable FGFR2-PPHLN1 fusion and ARAF mutations in intrahepatic cholangiocarcinoma. Nat. Commun., 6, 2015, 6087.
32. [32] Ong, C.K., Subimerb, C., Pairojkul, C., Wongkham, S., Cutcutache, I., Yu, W., et al. Exome sequencing of liver fluke-associated cholangiocarcinoma. Nat. Genet. 44 (2012), 690–693.
33. [33] Totoki, Y., Tatsuno, K., Covington, K.R., Ueda, H., Creighton, C.J., Kato, M., et al. Trans-ancestry mutational landscape of hepatocellular carcinoma genomes. Nat. Genet. 46 (2014), 1267–1273.
34. [34] Dong, H., Suzuki, N., Torres, M.C., Bonala, R.R., Johnson, F., Grollman, A.P., et al. Quantitative determination of aristolochic acid-derived DNA adducts in rats using 32P-postlabeling/polyacrylamide gel electrophoresis analysis. Drug Metab. Dispos. 34 (2006), 1122–1127.
35. [35] Pfau, W., Schmeiser, H.H., Wiessler, M., 32P-postlabelling analysis of the DNA adducts formed by aristolochic acid I and II. Carcinogenesis 11 (1990), 1627–1633.
36. [36] Arlt, V.M., Alunni-Perret, V., Quatrehomme, G., Ohayon, P., Albano, L., Gaid, H., et al. Aristolochic acid (AA)-DNA adduct as marker of AA exposure and risk factor for AA nephropathy-associated cancer. Int. J. Cancer 111 (2004), 977–980.
37. [37] Lord, G.M., Hollstein, M., Arlt, V.M., Roufosse, C., Pusey, C.D., Cook, T., et al. DNA adducts and p53 mutations in a patient with aristolochic acid-associated nephropathy. Am. J. Kidney Dis. 43 (2004), e11–7.
38. [38] Stiborova, M., Frei, E., Schmeiser, H.H., Arlt, V.M., Martinek, V., Mechanisms of enzyme-catalyzed reduction of two carcinogenic nitro-aromatics, 3-nitrobenzanthrone and aristolochic acid I: experimental and theoretical approaches. Int. J. Mol. Sci. 15 (2014), 10271–10295.
39. [39] Sidorenko, V.S., Attaluri, S., Zaitseva, I., Iden, C.R., Dickman, K.G., Johnson, F., et al. Bioactivation of the human carcinogen aristolochic acid. Carcinogenesis 35 (2014), 1814–1822.
40. [40] Meinl, W., Pabel, U., Osterloh-Quiroz, M., Hengstler, J.G., Glatt, H., Human sulphotransferases are involved in the activation of aristolochic acids and are expressed in renal target tissue. Int. J. Cancer 118 (2006), 1090–1097.
41. [41] Michl, J., Ingrouille, M.J., Simmonds, M.S., Heinrich, M., Naturally occurring aristolochic acid analogues and their toxicities. Nat. Prod. Rep. 31 (2014), 676–693.
42. [42] Sato, N., Takahashi, D., Chen, S.M., Tsuchiya, R., Mukoyama, T., Yamagata, S., et al. Acute nephrotoxicity of aristolochic acids in mice. J. Pharm. Pharmacol. 56 (2004), 221–229.
43. [43] Shibutani, S., Dong, H., Suzuki, N., Ueda, S., Miller, F., Grollman, A.P., Selective toxicity of aristolochic acids I and II. Drug Metab. Dispos. 35 (2007), 1217–1222.
44. [44] Schmeiser, H.H., Pool, B.L., Wiessler, M., Identification and mutagenicity of metabolites of aristolochic acid formed by rat liver. Carcinogenesis 7 (1986), 59–63.
45. [45] Rosenquist, T.A., Einolf, H.J., Dickman, K.G., Wang, L., Smith, A., Grollman, A.P., Cytochrome P450 1A2 detoxicates aristolochic acid in the mouse. Drug Metab. Dispos., 38, 2010, 8.
46. [46] Shibutani, S., Bonala, R.R., Rosenquist, T., Rieger, R., Suzuki, N., Johnson, F., et al. Detoxification of aristolochic acid I by O-demethylation: less nephrotoxicity and genotoxicity of aristolochic acid Ia in rodents. Int. J. Cancer 127 (2010), 1021–1027.
47. [47] Xiao, Y., Ge, M., Xue, X., Wang, C., Wang, H., Wu, X., et al. Hepatic cytochrome P450s metabolize aristolochic acid and reduce its kidney toxicity. Kidney Int. 73 (2008), 1231–1239.
48. [48] Xue, X., Xiao, Y., Zhu, H., Wang, H., Liu, Y., Xie, T., et al. Induction of P450 1A by 3-methylcholanthrene protects mice from aristolochic acid-I-induced acute renal injury. Nephrol. Dial. Transplant. 23 (2008), 3074–3081.
49. [49] Schmeiser, H.H., Schoepe, K.B., Wiessler, M., DNA adduct formation of aristolochic acid I and II in vitro and in vivo. Carcinogenesis 9 (1988), 297–303.
50. [50] Schmeiser, H.H., Nortier, J.L., Singh, R., Gamboa da Costa, G., Sennesael, J., Cassuto-Viguier, E., et al. Exceptionally long-term persistence of DNA adducts formed by carcinogenic aristolochic acid I in renal tissue from patients with aristolochic acid nephropathy. Int. J. Cancer 135 (2014), 502–507.
51. [51] Fernando, R.C., Schmeiser, H.H., Scherf, H.R., Wiessler, M., Formation and persistence of specific purine DNA adducts by 32P-postlabelling in target and non-target organs of rats treated with aristolochic acid I. IARC Sci. Publ. 16 (1993), 7–71.
52. [52] Scharer, O.D., Nucleotide excision repair in eukaryotes. Cold Spring Harb. Perspect. Biol., 5, 2013, a012609.
53. [53] Sidorenko, V.S., Yeo, J.E., Bonala, R.R., Johnson, F., Scharer, O.D., Grollman, A.P., Lack of recognition by global-genome nucleotide excision repair accounts for the high mutagenicity and persistence of aristolactam-DNA adducts. Nucleic Acids Res. 40 (2012), 2494–2505.
54. [54] Lukin, M., Zaliznyak, T., Johnson, F., de los Santos, C., Structure and stability of DNA containing an aristolactam II-dA lesion: implications for the NER recognition of bulky adducts. Nucleic Acids Res. 40 (2012), 2759–2770.
55. [55] Chen, L., Mei, N., Yao, L., Chen, T., Mutations induced by carcinogenic doses of aristolochic acid in kidney of Big Blue transgenic rats. Toxicol. Lett. 165 (2006), 250–256.
56. [56] Kohara, A., Suzuki, T., Honma, M., Ohwada, T., Hayashi, M., Mutagenicity of aristolochic acid in the lambda/lacZ transgenic mouse (MutaMouse). Mutat. Res. 515 (2002), 63–72.
57. [57] Feldmeyer, N., Schmeiser, H.H., Muehlbauer, K.R., Belharazem, D., Knyazev, Y., Nedelko, T., et al. Further studies with a cell immortalization assay to investigate the mutation signature of aristolochic acid in human p53 sequences. Mutat. Res. 608 (2006), 163–168.
58. [58] Liu, Z., Hergenhahn, M., Schmeiser, H.H., Wogan, G.N., Hong, A., Hollstein, M., Human tumor p53 mutations are selected for in mouse embryonic fibroblasts harboring a humanized p53 gene. Proc. Natl. Acad. Sci. U. S. A. 101 (2004), 2963–2968.
59. [59] Li, Y., Liu, Z., Guo, X., Shu, J., Chen, Z., Li, L., Aristolochic acid I-induced DNA damage and cell cycle arrest in renal tubular epithelial cells in vitro. Arch. Toxicol. 80 (2006), 524–532.
60. [60] Yang, L., Besschetnova, T.Y., Brooks, C.R., Shah, J.V., Bonventre, J.V., Epithelial cell cycle arrest in G2/M mediates kidney fibrosis after injury. Nat. Med. 16 (2010), 535–543.
61. [61] Broschard, T.H., Wiessler, M., Schmeiser, H.H., Effect of site-specifically located aristolochic acid DNA adducts on in vitro DNA synthesis by human DNA polymerase alpha. Cancer Lett. 98 (1995), 47–56.
62. [62] Attaluri, S., Bonala, R.R., Yang, I.Y., Lukin, M.A., Wen, Y., Grollman, A.P., et al. DNA adducts of aristolochic acid II: total synthesis and site-specific mutagenesis studies in mammalian cells. Nucleic Acids Res. 38 (2010), 339–352.
63. [63] Romanov, V., Whyard, T.C., Waltzer, W.C., Grollman, A.P., Rosenquist, T., Aristolochic acid-induced apoptosis and G2 cell cycle arrest depends on ROS generation and MAP kinases activation. Arch. Toxicol. 89 (2015), 47–56.
64. [64] Nassar, D., Latil, M., Boeckx, B., Lambrechts, D., Blanpain, C., Genomic landscape of carcinogen-induced and genetically induced mouse skin squamous cell carcinoma. Nat. Med. 21 (2015), 946–954.